

EMA/898469/2022

European Medicines Agency decision

P/0506/2022

of 2 December 2022

on the acceptance of a modification of an agreed paediatric investigation plan for bilastine (Bilaxten), (EMA-000347-PIP02-16-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0506/2022

of 2 December 2022

on the acceptance of a modification of an agreed paediatric investigation plan for bilastine (Bilaxten), (EMA-000347-PIP02-16-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0009/2019 issued on 3 January 2019, the decision P/0408/2019 issued on 4 December 2019, the decision P/0466/2020 issued on 1 December 2020 and the decision P/0526/2021 issued on 3 December 2021,

Having regard to the application submitted by Faes Farma S.A. on 1 July 2022 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 14 October 2022, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for bilastine (Bilaxten), eye drops, solution, ocular use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision covers all conditions, indications, pharmaceutical forms, routes of administration, measures, timelines, waivers and deferrals, as agreed in the decision P/88/2009 issued on 18 May 2009, including subsequent modifications thereof.

Article 3

This decision is addressed to Faes Farma S.A., Maximo Aguirre, 14, 48940 - Leioa, Spain.

EMA/PDCO/640010/2022
Amsterdam, 14 October 2022

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-000347-PIP02-16-M04

Scope of the application

Active substance(s):

Bilastine

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of allergic conjunctivitis

Pharmaceutical form(s):

Eye drops, solution

Route(s) of administration:

Ocular use

Name/corporate name of the PIP applicant:

Faes Farma S.A.

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Faes Farma S.A. submitted to the European Medicines Agency on 1 July 2022 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0009/2019 issued on 3 January 2019, the decision P/0408/2019 issued on 4 December 2019, the decision P/0466/2020 issued on 1 December 2020 and the decision P/0526/2021 issued on 3 December 2021.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 16 August 2022.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of allergic conjunctivitis

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- eye drops, solution, ocular use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition

Treatment of allergic conjunctivitis

2.1.1. Indication(s) targeted by the PIP

Symptomatic treatment of allergic conjunctivitis (seasonal and perennial) in children 2 years and older

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Eye drops, solution

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	Not applicable
Non-clinical studies	0	Not applicable
Clinical studies	1	Study 1 Double-blind, randomised, placebo-controlled, parallel-group trial to evaluate safety, tolerability and efficacy of bilastine ophthalmic solution 0.6% in children from 2 years to less than 18 years of age with seasonal (SAC) or perennial allergic conjunctivitis (PAC) (BOFT-0520-PED)

Extrapolation, modelling and simulation studies	2	Study 2 Simulation of bilastine systemic plasma profiles in children from 2 years to less than 18 years of age after ocular administration of bilastine, based on the systemic absorption observed for ophthalmic bilastine in adults and on the population systemic PK parameters previously estimated in children after oral bilastine (M&S-001) Study 3 Analysis of existing data on ocular bilastine in the treatment of allergic conjunctivitis in children from 2 years to less than 18 years of age (EXTRAPOL-001)
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By May 2023
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of allergic rhinoconjunctivitis

Authorised indication(s):

- Symptomatic treatment of allergic rhino-conjunctivitis (seasonal and perennial) and urticaria. Bilaxten is indicated in adults and adolescents (12 years of age and over).
- Symptomatic treatment of allergic rhino-conjunctivitis (seasonal and perennial) and urticaria. Bilaxten is indicated in children aged 6 to 11 years with a body weight of at least 20 kg.

2. Treatment of urticaria

Authorised indication(s):

- Symptomatic treatment of allergic rhino-conjunctivitis (seasonal and perennial) and urticaria. Bilaxten is indicated in adults and adolescents (12 years of age and over).
- Symptomatic treatment of allergic rhino-conjunctivitis (seasonal and perennial) and urticaria. Bilaxten is indicated in children aged 6 to 11 years with a body weight of at least 20 kg.

Authorised pharmaceutical form(s):

Tablet

Orodispersible tablet

Oral solution

Authorised route(s) of administration:

Oral use